Dudediligence.

Ensysce Biosciences, Inc

ENSCNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$3.4MSep ’24$1.3MDec ’24$1.3MMar ’25$1.4MJun ’25$493,104Sep ’25$1.9MDec ’25$960,999Mar ’26$1.2MJun ’26
Net income, by quarter
$661,769Sep ’24−$3.6MDec ’24−$1.9MMar ’25−$1.7MJun ’25−$3.7MSep ’25−$2.8MDec ’25−$3.6MMar ’26−$2.6MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$3.5M$2.5M$2.2M$5.2M$5.1M
Operating income−$19.9M−$24.2M−$10.7M−$6.7M−$10.2M
Net income−$29.1M−$24.2M−$10.6M−$8.0M−$10.2M
Operating cash flow−$8.2M−$17.9M−$10.8M−$7.5M−$7.8M
Free cash flownone on filenone on filenone on filenone on file−$7.9M
Cash$12.3M$3.1M$1.1M$3.5M$4.3M
Shares outstanding1.2M534.5K209.7K1.4M4.6M